KIDRON Capital Assets announces first close of women's health VC fund
Kidron targets untapped opportunities in women's health across Europe, the USA and Israel
KIDRON Capital Assets, a first-of-its-kind fund with a presence in Israel has marked it first close.
Led by two female General Partners, KIDRON is dedicated to women’s health and targets untapped opportunities across Europe, the USA and Israel.
KIDRON's portfolio includes various sectors, including medical devices, diagnostics, digital health, therapeutics, and services.
“This strategic diversity ensures our ability to impact various facets of women's health while driving innovation, positive change, and outstanding returns for our investors,” it said in its announcement.
The fund has now made inaugural investments in three US-based companies:
Beyond Medicine: Pioneering the longevity space with cutting-edge solutions redefining human health span by targeting mitochondrial health, improving skin rejuvenation and alleviating menopausal symptoms.
Portal: Revolutionising a $1B market with a simplified, scalable solution for oncology clinics, backed by a proven team with six exits to giants like Medtronic and BD, Portal's approach enhances access to care and quality of life for women facing cancer, signalling strong potential for investor gains.
Renal Guard: The only clinically validated solution to prevent Acute Kidney Injury (AKI), a risk heightened for women during cardiac surgeries. With its CE approval, initial sales and investigation in the US, Renal Guard is redefining standards of care, ensuring women's health and safety during common surgical procedures, while promising substantial returns for investors.
.